These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 12002766)
1. Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Niesvizky R; Siegel D; Glassman J; Straus D; Fine J; Lyons L; Michaeli J Leuk Lymphoma; 2002 Mar; 43(3):607-12. PubMed ID: 12002766 [TBL] [Abstract][Full Text] [Related]
2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
3. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138 [TBL] [Abstract][Full Text] [Related]
4. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. García-Sanz R; González-Porras JR; Hernández JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; López R; Grande-García C; Alegre A; Vargas-Pabón M; Gutiérrez ON; Rodríguez JA; San Miguel JF Leukemia; 2004 Apr; 18(4):856-63. PubMed ID: 14973508 [TBL] [Abstract][Full Text] [Related]
5. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. Luo SK; Li J; Hong WD; Zhao Y; Tong XZ Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805 [TBL] [Abstract][Full Text] [Related]
6. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948 [TBL] [Abstract][Full Text] [Related]
7. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. Suguro M; Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A Am J Hematol; 2000 Oct; 65(2):132-5. PubMed ID: 10996830 [TBL] [Abstract][Full Text] [Related]
8. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Barlogie B; Smallwood L; Smith T; Alexanian R Ann Intern Med; 1989 Apr; 110(7):521-5. PubMed ID: 2647015 [TBL] [Abstract][Full Text] [Related]
9. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G J Clin Oncol; 2003 Jul; 21(14):2732-9. PubMed ID: 12860952 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793 [TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257 [TBL] [Abstract][Full Text] [Related]
12. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C J BUON; 2007; 12(1):41-4. PubMed ID: 17436400 [TBL] [Abstract][Full Text] [Related]
13. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
14. The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients. Celesti L; Clavio M; Poggi A; Casciaro S; Vallebella E; Gobbi M Haematologica; 1997; 82(3):351-3. PubMed ID: 9234590 [TBL] [Abstract][Full Text] [Related]
15. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690 [TBL] [Abstract][Full Text] [Related]
16. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]